After treating vaginal atrophy with local estrogens, sexual satisfaction for postmenopausal women and their male partners improves, according to the results of a survey published online in the journal Menopause.
After treating vaginal atrophy with local estrogens, sexual satisfaction for postmenopausal women and their male partners improves, according to the results of a survey published online in the journal Menopause.1
The Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) online survey polled a weighted sample of 1,000 married or cohabitating postmenopausal women between the ages of 55 to 65 who experienced vaginal discomfort, along with their male partners. In the survey population, vaginal discomfort caused 58% of the women to avoid intimacy and 64% experienced loss of libido and pain during sex. Nearly one-third of couples stopped having sex altogether, citing vaginal discomfort as the cause.
Among women who used local estrogen therapy, 56% reported less painful intercourse, 41% reported more satisfying sex and 29% reported an improved sex life. Among male partners, 57% reported that their partner’s use of local estrogen therapy made them look forward to having sex again.
Laura Corio, MD, a gynecologist in New York City, commented on the study in Medscape, saying, “There are a lot of local vaginal estrogens that we can use that will thicken the lining of the vagina and help with sex. One thing that's important to remember is, if you can feel better and continue to have sex, it'll only get better with sex. Use it or lose it."2
1. Simon, James A., et al. Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners.Menopause. Published online June 3, 2013.
2. Waknine, Y. (2013, June 10). Sex Improves With Vaginal Atrophy Treatment, Survey Finds. Medscape. Retrieved 6/17/2013 from http://www.medscape.com/viewarticle/805573.
OASIS-1 trial reports reduced VMS frequency and severity from elinzanetant
May 17th 2024A recent study showcased at the 2024 ACOG Annual Clinical & Scientific Meeting unveils elinzanetant's efficacy in alleviating vasomotor symptoms, sleep disturbances, and enhancing menopause-related quality of life in postmenopausal women.
Read More
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Study links premature menopause to musculoskeletal pain and sarcopenia risks
May 1st 2024A recent study revealed an association between premature menopause and increased risks of musculoskeletal pain and sarcopenia, emphasizing the potential benefits of hormone therapy in mitigating long-term effects.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More